Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease

Abstract

Background The promise of Alzheimer’s disease (AD) biomarkers has led to their incorporation in new diagnostic criteria and in therapeutic trials; however, significant barriers exist to widespread use. Chief among these is the lack of internationally accepted standards for quantitative metrics. Hippocampal volumetry is the most widely studied quantitative magnetic resonance imaging (MRI) measure in AD and thus represents the most rational target for an initial effort at standardization. Methods and Results The authors of this position paper propose a path toward this goal. The steps include: 1) Establish and empower an oversight board to manage and assess the effort, 2) Adopt the standardized definition of anatomic hippocampal boundaries on MRI arising from the EADC-ADNI hippocampal harmonization effort as a Reference Standard, 3) Establish a scientifically appropriate, publicly available Reference Standard Dataset based on manual delineation of the hippocampus in an appropriate sample of subjects (ADNI), and 4) Define minimum technical and prognostic performance metrics for validation of new measurement techniques using the Reference Standard Dataset as a benchmark. Conclusions Although manual delineation of the hippocampus is the best available reference standard, practical application of hippocampal volumetry will require automated methods. Our intent is to establish a mechanism for credentialing automated software applications to achieve internationally recognized accuracy and prognostic performance standards that lead to the systematic evaluation and then widespread acceptance and use of hippocampal volumetry. The standardization and assay validation process outlined for hippocampal volumetry is envisioned as a template that could be applied to other imaging biomarkers.

Alzheimer Disease: New Concepts on Its Neurobiology and the Clinical Role Imaging Will Play

“…In an ideal world, a subject could be imaged with a unit by any vendor. An analysis software pipeline would be used to analyze that subject's scan, extract quantitative data, compare those data to a standardized database, and assign the subject a probabilistic differential diagnosis and an imaging-based disease severity rank (282). Ideally this would happen "online" on the imaging unit.…”

Resting metabolic connectivity in Alzheimer’s disease

“…Consistent with this pathology, magnetic resonance imaging (MRI) in early stage AD demonstrates MTL atrophy [7,8] while functional imaging with 18 F-FDG PET reveals hypometabolism with a characteristic parietotemporal and posterior cingulate pattern [9].…”

Magnetic resonance imaging and positron emission tomography in the diagnosis of neurodegenerative dementias

“…Visual inspection of MR images, although easy to perform, is not adequate for the diagnosis of primary neurodegenerative diseases. To enhance the accuracy of atrophy detection and allow its use as a biomarker for the diagnosis of dementia, a standardized quantification of atrophy is required (Jack et al, 2011). Quantification of atrophy requires manual segmentation of the gray matter.…”